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GARAVITO G.*,***, BERTANI S.**,***, RINCON J.*, MAUREL S.***, MONJE M.C.***, LANDAU I.**,
VALENTIN A.*** & DEHARO E.***
Summary: 
Methylene blue (MB) is the oldest synthetic antimalarial. It is not
used anymore as antimalarial but should be reconsidered. For this
purpose we have measured its impact on both chloroquine
sensitive and resistant Plasmodium strains. We showed that around
5 nM of MB were able to inhibit 50 % of the parasite growth
in vitro and that late rings and early trophozoites were the most
sensitive stages; while early rings, late trophozoites and schizonts
were less sensitive. Drug interaction study following fractional
inhibitory concentrations (FIC) method showed antagonism with
amodiaquine, atovaquone, doxycycline, pyrimethamine; additivity
with artemether, chloroquine, mefloquine, primaquine and synergy
with quinine. These results confirmed the interest of MB that could
be integrated in a new low cost antimalarial combination therapy.
Résumé : ACTIVITÉ DU BLEU DE MÉTHYLÈNE EN COMBINAISON AVEC
DES ANTIPALUDIQUES CONTRE ES STADES SANGUINS DE PLASMODIUM
FALCIPARUM
Le bleu de méthylène (BM) est l’antipaludique de synthèse le plus
ancien. Il n’est désormais plus employé comme antipaludique,
mais son usage devrait être reconsidéré. Nous avons mesuré son
effet sur des souches de Plasmodium chloroquino-sensibles et
chloroquino-résistantes. Nous avons montré que 5 nM de BM
inhibent 50 % du développement parasitaire in vitro et que les
stades anneaux mûrs et trophozoites jeunes sont les stades les plus
sensibles tandis que les trophozoites âgées, les schizontes et les
anneaux jeunes sont les moins sensibles. L’étude de l’interaction de
drogues selon la méthode des concentrations inhibitrices
fractionnelles ou FIC montre que l’association avec le MB est:
antagoniste avec l’amodiaquine, l’atovaquone, la doxycycline et
la pyriméthamine, additive avec l’artéméther, la chloroquine, la
méfloquine et la primaquine et synergique avec la quinine. Ces
résultats confirment l’intérêt du BM qui pourrait être intégré dans
une nouvelle thérapie antipaludique de combinaison à prix réduit.
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didate must be effective within a three-day regimen,
safe in small children (< 6 months) and pregnant women,
easy to package, cheap and have a low propensity to
generate resistance (Baird, 2005; Pink et al., 2005).
Adapted to oral administration, MB gathers all these
features except one: it is not new anymore. In 1891,
Ehrlich & Guttmann (1891) used MB to treat two
patients infected by Plasmodium; for the first time a
synthetic drug was shown to be active against malaria.
Later, MB along with quinine, served as structural star-
ting points for the development of 8-aminoquinoline
(pamaquine) and 9-aminoacridine (mepacrine, quina-
crine) in 1925 and 1930, respectively (Schulemann,
1932). Since that time, few works on the antimalarial
properties of MB have been reported because it was
thought to enhance hemolysis in case of glucose-6-
phosphate-deshydrogenase (G6PD) deficiency (Schirmer
et al., 2003) and could stain the tissues of MB-treated
people (Wainwright & Amaral, 2005). Nevertheless,
Mandi et al. (2005) and Meissner et al. (2005) found
recently that G6PD deficiency did not compromise the
use of MB for malaria treatment, even in class III G6PD
deficient young children. Recently, Akoachere et al.
(2005) studied the interaction between MB and clas-
INTRODUCTION
Malaria remains one of the most important para-sitosis in tropical developing countries, killing1-3 million people (mostly children) in sub-
Saharan Africa, and causing disease in 300-500 million
people a year. Despite international commitment to
control and research, the reality for many patients is
much as it was twenty years ago: they still die because
being unable to access treatment for economic reasons.
Moreover available drugs are not efficient due to para-
site resistance (Olliaro, 2005). In this context, new, safe,
affordable and efficient drugs against resistant strains
of Plasmodium are needed. In addition to be effec-
tive against drug resistant malaria, an ideal new can-
sical antimalarial drugs, and found MB to be antago-
nistic with amodiaquine and chloroquine. This sounded
strange to us, as MB is an exceptionally weak base
(pKa 0-l) (Keene et al., 1965; Pottier et al., 1975) accu-
mulating inside malaria-infected red blood cell in
which it is reduced and probably concentrated in the
food vacuole where it inhibits the formation of hemo-
zoin (Atamna et al., 1996), just as 4-aminoquinolines
do. Moreover, MB inhibits parasite glutathione reduc-
tase thus jeopardizes glutathione functionality (Färber
et al., 1998). Instead of antagonise, this phenomenon
should enhance chloroquine activity, which is closely
related to glutathione levels (Meierjohann et al., 2002).
We thus re-examined herein the activity of MB on
African and South-American P. falciparum strains,
determined the most sensitive parasitic stage and stu-
died the association of MB with classical antimalarial
drugs, as the spread of multidrug-resistant Plasmodium
strains favours the use of combinations to protect the




All chemicals were from Sigma-Aldrich (L’Isled’Abeau Chesnes, France) except artemether(ART) from Cambrex (Verviers, Belgium), atova-
quone (ATO) was a gift from GlaxoSmithKline (Marly-
le-Roi, France) and mefloquine (MEF) from Hoffmann-
La Roche (Basel, Switzerland).
Amodiaquine (AMO), ART, ATO, chloroquine (CQ),
doxycycline (DOX), MB, primaquine (PRIM), pyrime-
thamine (PYR), quinine (Q) and MEF were dissolved
in appropriate solvents and then with RPMI 1640
medium (Cambrex). All final concentrations of solvent
were < 0.01 %, as recommended by Ye et al. (1983).
PLASMODIUM FALCIPARUM IN VITRO
Four uncloned strains of P. falciparum were used: F32-
Tanzania, HB3-Honduras, FcM29-Cameroon and FcB1-
Colombia. Parasites were cultured according to Trager
and Jensen (1976) on human type O+ erythrocytes in
RPMI 1640 medium supplemented with 25 mM HEPES
buffer, 10 % AB human serum (3-5 % hematocrit), 2 mg
of sodium bicarbonate/ml, 0.5 µg of gentamicin/ml and
incubated at 37°C in a reduced oxygen environment (e.g.
a custom mixture of 5 % CO2, 5 % O2 and 90 % N2).
BIOASSAYS
The in vitro drug study was adapted from the micro-
dilution technique of Desjardins et al. (1979). Each drug
was tested for 48 h in triplicate in 96-well plates (TPP,
Switzerland) with culture at ring stage (synchronization
by 5 % D-sorbitol lysis; Sigma-Aldrich) and 0.5-2 %
parasitemia (hematocrit: 1.5 %). Parasite growth was
estimated by [3H]-hypoxanthine (PerkinElmer, Courta-
boeuf, France) incorporation (1.44 µCi/ml); plates were
frozen-defrosted and each well was harvested onto a
glass fibber filter (PerkinElmer). Incorporated [3H]-
hypoxanthine was then determined with a β-counter
(1450-Microbeta Trilux, Wallac-PerkinElmer); controls
were performed to assess the background (negative
control) and the parasite growth (positive control). The
IC50 of the different strains of P. falciparum were deter-
mined with a linear least square regression analysis.
Stage specificity tests were performed on FcB1 strain.
Drugs were tested in triplicate against a culture syn-
chronized for a 6 h period by treatment with Plasmion
(Laboratoire Fresenius Kabi, France) and consecutive
5 % D-sorbitol lysis (Lelièvre et al., 2005). After each
exposition, treated wells were washed twice with RPMI
and cells returned to normal culture conditions until
time zero plus 48 h (Valentin et al., 1997). [3H]-hypoxan-
thine (0.5 µCi/well) was then added and plates were
incubated for another 36 h. Results were expressed as
percentage of inhibition versus controls without drug.
Combination experiments were performed with FcM29
strain. Drugs were combined in 96 wells microtitration
test plates at various fractions of their respective IC50.
Results were expressed as the mean sums of the frac-
tional inhibitory concentrations (FIC), defined as (IC50
of drug A in mixture/IC50 of drug A alone) + (IC50 of
drug B in mixture/IC50 of drug B alone) for each fixed
concentration (Berenbaum, 1978; Canfield et al., 1995).
Three types of drug interaction were defined as fol-
lows: additivity, sum of FIC = 1; synergism, sum of
FIC < 1; and antagonism, sum of FIC > 1 (Ringwald et
al., 1999; Ankoachere et al 2005). We followed this
classification to get comparable results with Ankoa-
chere study, although Odds (2003) suggested much
more restrictive definitions: synergism (FIC ≤ 0.5), no
interaction (FIC > 0.5-4) and antagonism (FIC > 4)
(Odds, 2003).
RESULTS
Activities of the ten drugs against the four strainsof P. falciparum are listed in Table I. FcB1strain was sensitive to AMO, MEF, PYR and Q
and resistant to ART, ATO, CQ and DOX. The F32
strain was sensitive to AMO, ART and CQ and resis-
tant to ATO, DOX, MEF, PYR and Q. The HB3 strain
was sensitive to all the tested drugs. F32 and HB3 were
similarly sensitive to CQ while FcB1 and FcM29 were
resistant, FcM29 being almost three times more resis-
tant than FcB1. FcM29 was thus selected for the drug
interaction tests. It was sensitive to AMO, Q and resis-
IC50 (nM) Res istan ce FIC Meanb 
Compounds F32 HB3 FcBl FcM29 threshold" FcM29 Interaction s 
Amodia quine 19 23 22 33 > 60 1.28 ± 0.11 Antagonism 
Artemether 0,4 10 14 16 > 12 0.95 ± 0.05 Additivity 
Atovaquone 20 0,1 22 188 >7 1.24 ± 0.17 Antagonism 
Chloroquine 70 36 186 600 > 100 1.03 ± 0.08 Additivity 
Doxycycline 26,185 4,446 12,540 22,632 > 9,600 1.44 ± 0.28 Antagonism 
Mefloquine 401 31 16 106 > 30 0.97 ± 0.12 Additivity 
Methylene blue 5 4 8 5 ND 
Primaquine 4,627 ND 432 13,20 ND 0.93 ± 0.08 Additivity 
Pyrimethamine 6,882 ND 97 21,774 > 2,000 1.15 ± 0.10 Antagonism 
Quinine 835 208 423 331 > 500 0.74 ± 0.11 Synergy 
Interactions : additivity, sum of FIC = 1; synergism, sum of FIC < 1; and antagonism, sum of FIC > 1 (according to Ankoachere et al., 
2005). 
"Information provided by the Centre national de référence sur la clùmiorésistance du paludisme, Institut Pasteur de Guyane; bFIC mean = 
mean sum of fractional inhibitory concentrations ± SD (obtained from 5 to 20 determinations); ND: not determined. 
Table 1. - ln vttro activity of MB blue and classical antimalarials (alone or in combination) against different strains of P. falctparnm. 
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Fig. 1. - Sensitivity of the different stages of P.falciparnm FcBl strain to increasing doses of methylene blue and quinine: (A) methylene 
blue; (B) quinine. 
tant to the other drugs (except MB). MB was highly 
active against the four strains of P. falciparum, being 
the most active of ail tested drugs. When tested on 
highly synchronized parasites, it appeared that late rings 
and early trophozoites were the most sensitive stages 
to MB (Fig. 1). This was similar for Q who additionally 
displayed good activity on late trophozoites (Fig. 1). 
Early rings were moderatly sensitive, whereas early and 
late schizonts showed the lowest susceptibility for the 
two drugs. Late trophozoites were sensitive to Q but 
not to MB. 
Results of the combination studies following the cri-
teria defined by Ankoachere et al. (2005) indicated that 
interactions with MB ranged from antagonism to syner-
gism (see Table I and Fig. 2): antagonism with AMO, 
ATO, DOX and PYR; additivity with ART, CQ, MEF and 
PRIM; and synergy with quinine. According to the scale 
defined by Odds (2003), there is no interaction bet-
ween MB and ail tested drugs. 
DISCUSSION AND CONCLUSION 
Methylene blue has already been shown to be active alone in vitro against laboratory-adapted strains from various geographic regions, with 
IC50 ranging from 3 to 11 nM (Atamna et al., 1996; Ven-
nerstrom et al., 1995). Our results further demonstrated 
the in vitro activity of MB against F32 and HB3 chloro-
quine-sensitive strains, and FcM29 and FcBl chloro-
quine-resistant strains of P. falciparum with the same 
range of activity (- 5 nM). Akoachere et al. (2005) 
showed that MB was active against KI-South East Asia 
and Dd2-Indochina chloroquine-resistant strains at 
around 7 nM. That means that MB is strongly active 
against strains from ail over the world including chlo-
roquine-resistant strains. Subjecting a synchronized cul-
ture to pulses of MB every 8 h for 48 h (Fig. 1) we 
showed that MB inhibited around 60 % of the parasite 
growth between the 8th to the 24th h of the parasite cycle 
(at 6.25 nM) when the production of plasmodial RNA 
and protein are maximal (Arnot & Gull, 1998). That is 
consistent with the fact that the antimalarial activity of 
MB depends on the Plasmodium antioxydant defences, 
which are fully functional at the late ring-early tropho-
zoite stages when intensive digestion of haemoglobin 
occurs. This is also correlated with the peak of expres-
sion of plasmodial glutathione reductase (PF140192), 
which is targeted by MB (Farber et al., 1998), starting 
8 hours post invasion and reaching its maximum at the 
24th hour of the intraerythrocytic cycle (PlasmoDB, 2005). 
With the emergence and spread of drug resistance in 
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sents an effective approach in curbing the development 
of resistance of the parasite to the commercially avai-
lable compounds (Gupta et al., 2002). Additionally it 
may reduce toxicity and shorter treatment regimens 
(Pink et al., 2005). Akoachere et al. (2005) found MB 
to be antagonistic with AMO, CQ, PRIM and PYR; addi-
tive with MEF and Q; synergistic with ART, artemisinin 
and artesunate, against P.falciparum Kl strain in cul-
ture. Antagonism with AMO and CQ is surprising as 
MB (like 4-aminoquinolines) concentrated in Plasmo-
dium food vacuole where it inhibits the formation of 
hemozoin (Atamna et al., 1996). It is also known to 
inhibit parasite glutathione reductase (Farber et al., 
100 
' ATO ', ,, 
80 ',, 






40 ... , 
' ', ', ,, ,, 
20 ',, ,, 
' ', ' 
" ', 
0 









' ' ' ' ,, ' 40 40 40 ,._ 
",, ', 
' ' ' 20 20 ', 20 ,...._, 
' '\ 
' ' ' ' ', ', 0 0 0 
0 20 40 60 80 100 0 20 40 60 80 100 0 20 40 60 80 100 
MS MS MS 
100 100 100 
' PRIM PYR Q ,, 


















0 0 0 
0 20 40 60 80 100 0 20 40 60 80 100 0 20 40 60 80 100 
MS MS MS 
The straight line in each panel represents additivity. Points located below this line indicate synergism, data points above the line indicate 
antagonism. 
AMO = amodiaquine ; ART = artemether; ATO = atovaquone; CQ = chloroquine; DOX = doxycycline; MEF = mefloquine; MB = methylene 
blue ; PRIM = primaquine ; PYR = pyrimethamine; Q = quinine. 
Fig. 2. - Jsobolograms of cln1g interactions between MB and other antimalarial dmgs. 
1998) enhancing chloroquine activity (Meierjohann et
al., 2002). We thus decided to study the interaction
between MB and known antimalarials with a slightly
different model from that of Akoachere et al. (2005).
We started with higher (1-2 %) parasitemia and initiated
radio labelling at time zero plus 32 h for 16 h. We
ended the experiment after 48 h incubation. We found
antagonism with MB + AMO, ATO, DOX and PYR while
in the Akoachere’s study AMO, CQ, PRIM and PYR
were antagonist. Although AMO belongs to the same
chemical class of compounds as CQ, the 4-aminoqui-
nolines, the association of MB and this drug was anta-
gonist in both studies, this must be due to the fact that
the antimalarial activity of AMO is mainly exerted
through its metabolite, desethylamodiaquine (Mariga et
al., 2005). DOX and PYR are very cheap, unfortuna-
tely these products were antagonist with MB against
P. falciparum FcM29 strain (DOX was not tested in
Akoachere’s study and PYR was also found antagonist).
In our hands, the association of MB with Q was syner-
gic (additive in Akoachere’s study). Q present simila-
rities with MB: we showed that the activity of the two
drugs was directed against initial stages of the blood
cycle (Q being also slightly active against late tropho-
zoites). As MB, Q is a weak membrane-soluble base,
accumulating in the acidic digestive vacuole contents
where it undergoes protonation. Unfortunately Q use
is limited by its long therapy duration, entailing poor
adherence with high risk of failure, and its potential
toxicity in people with G6PD deficiency (Baird, 2005).
Additive interactions were also observed between MB and
ART, CQ, MEF and PRIM. ART is a drug of choice and
was found to be synergic in Akoachere’s study (Akoa-
chere et al., 2005). Despite a prohibitive price making
their deployment difficult, artemisinin-based combina-
tion therapies (ACTs) are the best antimalarial treatments
available nowadays and are recommended by WHO
since 2001 (Mutabingwa, 2005). MEF was additive in both
studies but it is not an optimal candidate because per-
sistence of subinhibitory concentrations for long periods
(elimination t1/2, 2 weeks) (Karbwang et al., 1988; Mansor
et al., 1989). CQ remains one of the cheapest antimala-
rial easily accessible in developing countries. Rengel-
shausen et al. (2004) showed that oral co-administration
of MB and CQ did not show major pharmacokinetic inter-
actions confirming the feasibility of this combination.
Nevertheless, in a trial conducted in Burkina Faso, where
high resistance of Plasmodium to CQ was reported,
Meissner et al. (2006) found that the CQ-MB combina-
tion was not sufficently effective in the treatment of
uncomplicated malaria in young children. This observa-
tion was correlated with antagonism reported by Akoa-
chere et al. (2005), between CQ and MB.
In conclusion, according to Akoachere et al. (2005) cri-
teria: additivity with MEF and antagonism with AMO
were supported in both studies. Q was synergic in our
hands and additive in their study. ART was synergic
in Akoachere’s study and additive for us. On the
contrary we found additivity with CQ and PRIM while
antagonism was claimed by Akoachere et al. (2005).
We also showed antagonism with DOX and ATO, not
tested elsewhere. These discrepancies suggest that in
vivo studies with animal models should be conducted
to determine adequate associations.
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